Orexo to present at Rodman & Renshaw 5th Annual Global Healthcare Conference

Orexo to present at Rodman & Renshaw 5th Annual Global Healthcare Conference

Uppsala, Sweden - Orexo AB today announced that the company will present at the
Rodman & Renshaw 5th Annual Global Conference on May 20th.

The conference is being held on May 19-20 at the Le Meridien Beach Plaza Hotel
in Monte Carlo, Monaco and attracts investors from the international financial
community. The full conference schedule can be found on
www.rodmanrenshaw.com/eu08conference
The slides from Orexo´s presentation will subsequently be available on
www.orexo.com.


For further information, please contact: 
Torbjörn Bjerke, President and CEO, Orexo AB
Tel: +46 (0)708-66 19 90
E-mail: torbjorn.bjerke@orexo.com

Claes Wenthzel, Executive Vice President & CFO, Orexo AB 
Tel: +46 (0)18-780 88 44 
E-mail: claes.wenthzel@orexo.com


TO THE EDITORS
About Orexo

Orexo is a pharmaceutical company, focusing on development of new, patented
drugs by combining well-documented substances with innovative technologies, and
the development of new treatments for respiratory and inflammatory diseases.

Orexo has a broad and competitive late-stage product portfolio, including two
marketed products, five products in clinical phase and two undergoing
registration. 

To date, Orexo have out-licensed the market rights for Rapinyl for the US, the
EU and Japan markets, the world-wide market rights for Sublinox (OX22) and
OX-NLA, and a out-license and research collaboration with Boehringer Ingelheim
regarding the development of a new class of drugs to treat pain and
inflammation. Also, Orexo has established a Nordic sales force by entering into
a joint venture with ProStrakan.

Orexo has head office in Uppsala and is listed on the OMX Nordic Exchange
Stockholm, Small Cap (ticker: ORX).  

www.orexo.com